The management of iron deficiency in inflammatory bowel disease - an online tool developed by the RAND/UCLA appropriateness method
Walter Reinisch(Medical University of Vienna), Herman Stoevelaar(Barnes-Jewish Hospital), Fernando Gomollón(Universidad de Zaragoza), Bjørn Moum(University of Oslo), Gerassimos J. Mantzaris(European CanCer Organisation), Axel Dignaß(Goethe University Frankfurt), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Silvio Danese(IRCCS Ospedale San Raffaele), Péter L. Lakatos(McGill University), Stefan Lindgren(Skåne University Hospital), Murat Törüner(Ankara University), Pierre Michetti(University of Bern), Charlie W. Lees(Western General Hospital), C. Janneke van der Woude(Radboud University Nijmegen), Yehuda Chowers(Cleveland Clinic), Ole Haagen Nielsen(University of Copenhagen)
Cited by 28
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k